HRP20230251T1 - Derivati tiazolopridina kao antagonisti adenozinskih receptora - Google Patents
Derivati tiazolopridina kao antagonisti adenozinskih receptora Download PDFInfo
- Publication number
- HRP20230251T1 HRP20230251T1 HRP20230251TT HRP20230251T HRP20230251T1 HR P20230251 T1 HRP20230251 T1 HR P20230251T1 HR P20230251T T HRP20230251T T HR P20230251TT HR P20230251 T HRP20230251 T HR P20230251T HR P20230251 T1 HRP20230251 T1 HR P20230251T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- image
- cancer
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17184272 | 2017-08-01 | ||
| EP18733649.0A EP3661941B1 (en) | 2017-08-01 | 2018-07-02 | Thiazolopyridine derivatives as adenosine receptor antagonists |
| PCT/EP2018/067797 WO2019025099A1 (en) | 2017-08-01 | 2018-07-02 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230251T1 true HRP20230251T1 (hr) | 2023-04-14 |
Family
ID=59506176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230251TT HRP20230251T1 (hr) | 2017-08-01 | 2018-07-02 | Derivati tiazolopridina kao antagonisti adenozinskih receptora |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11186592B2 (enExample) |
| EP (1) | EP3661941B1 (enExample) |
| JP (1) | JP7336434B2 (enExample) |
| KR (1) | KR102717280B1 (enExample) |
| CN (1) | CN110997681B (enExample) |
| AU (1) | AU2018309265B2 (enExample) |
| CA (1) | CA3071575A1 (enExample) |
| DK (1) | DK3661941T3 (enExample) |
| ES (1) | ES2940407T3 (enExample) |
| FI (1) | FI3661941T3 (enExample) |
| HR (1) | HRP20230251T1 (enExample) |
| HU (1) | HUE061308T2 (enExample) |
| IL (1) | IL272284B2 (enExample) |
| LT (1) | LT3661941T (enExample) |
| PL (1) | PL3661941T3 (enExample) |
| PT (1) | PT3661941T (enExample) |
| RS (1) | RS64035B1 (enExample) |
| SG (1) | SG11202000823WA (enExample) |
| SI (1) | SI3661941T1 (enExample) |
| TW (1) | TWI850199B (enExample) |
| WO (1) | WO2019025099A1 (enExample) |
| ZA (1) | ZA202001295B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR117844A1 (es) * | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
| CN112174943A (zh) * | 2019-07-03 | 2021-01-05 | 四川大学 | 一种吲哚-2-酮类化合物在制备防治口腔细菌产品中的用途 |
| EP4351640A1 (en) | 2021-06-07 | 2024-04-17 | Ares Trading S.A. | Combination treatment of cancer |
| MX2025000931A (es) | 2022-08-02 | 2025-03-07 | Merck Patent Gmbh | Nuevas formas cristalinas de [7-(3,6-dihidro-2h-piran-4-il)-4-metoxi-tiazolo[4,5-c]piridin-2-il]-amida de acido (s)-7-oxa-2-aza-espiro[4.5]decano-2-carboxilico y formas cocristalinas de las mismas |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207554A (en) | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| US4125828A (en) | 1972-08-04 | 1978-11-14 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| US6579868B1 (en) | 1998-01-05 | 2003-06-17 | Eisai Co., Ltd. | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| WO2001002400A1 (en) | 1999-07-02 | 2001-01-11 | Eisai Co., Ltd. | Fused imidazole compounds and remedies for diabetes mellitus |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| RU2251419C2 (ru) * | 2000-06-21 | 2005-05-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензотиазола |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| US6713499B2 (en) * | 2001-12-12 | 2004-03-30 | Hoffman-La Roche Inc. | 7-Amino-benzothiazole derivatives |
| JP2005516917A (ja) | 2001-12-12 | 2005-06-09 | アメリカ合衆国 | 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法 |
| WO2004092171A2 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists |
| US6872833B2 (en) * | 2003-04-14 | 2005-03-29 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| ATE389652T1 (de) * | 2003-05-19 | 2008-04-15 | Hoffmann La Roche | Benzothiazol-derivate als liganden des adenosinrezeptors |
| WO2005028484A1 (en) * | 2003-09-19 | 2005-03-31 | F. Hoffmann-La Roche Ag | Thiazolopyridine derivatives as adenosine receptor ligands |
| AU2005263500B2 (en) | 2004-07-22 | 2011-02-24 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
| KR101077295B1 (ko) * | 2006-05-18 | 2011-10-26 | 에프. 호프만-라 로슈 아게 | 아데노신 a2b 수용체 길항물질로서의 티아졸로-피라미딘/피리딘 우레아 유도체 |
| US8168785B2 (en) * | 2009-06-17 | 2012-05-01 | Biotie Therapies, Inc. | Benzothiazole derivatives |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
-
2018
- 2018-07-02 WO PCT/EP2018/067797 patent/WO2019025099A1/en not_active Ceased
- 2018-07-02 HR HRP20230251TT patent/HRP20230251T1/hr unknown
- 2018-07-02 RS RS20230195A patent/RS64035B1/sr unknown
- 2018-07-02 CN CN201880050465.4A patent/CN110997681B/zh active Active
- 2018-07-02 CA CA3071575A patent/CA3071575A1/en active Pending
- 2018-07-02 FI FIEP18733649.0T patent/FI3661941T3/fi active
- 2018-07-02 US US16/635,356 patent/US11186592B2/en active Active
- 2018-07-02 JP JP2020505412A patent/JP7336434B2/ja active Active
- 2018-07-02 KR KR1020207006084A patent/KR102717280B1/ko active Active
- 2018-07-02 IL IL272284A patent/IL272284B2/en unknown
- 2018-07-02 SI SI201830863T patent/SI3661941T1/sl unknown
- 2018-07-02 PT PT187336490T patent/PT3661941T/pt unknown
- 2018-07-02 AU AU2018309265A patent/AU2018309265B2/en active Active
- 2018-07-02 EP EP18733649.0A patent/EP3661941B1/en active Active
- 2018-07-02 PL PL18733649.0T patent/PL3661941T3/pl unknown
- 2018-07-02 SG SG11202000823WA patent/SG11202000823WA/en unknown
- 2018-07-02 ES ES18733649T patent/ES2940407T3/es active Active
- 2018-07-02 DK DK18733649.0T patent/DK3661941T3/da active
- 2018-07-02 HU HUE18733649A patent/HUE061308T2/hu unknown
- 2018-07-02 LT LTEPPCT/EP2018/067797T patent/LT3661941T/lt unknown
- 2018-07-31 TW TW107126410A patent/TWI850199B/zh active
-
2020
- 2020-02-28 ZA ZA2020/01295A patent/ZA202001295B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241385T1 (hr) | Derivati tiazolopiridina kao antagonisti receptora adenozina | |
| JP7136886B2 (ja) | Hivカプシド阻害剤の固体形態 | |
| JOP20210241A1 (ar) | مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان | |
| AU2017208133B2 (en) | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof | |
| CL2021000628A1 (es) | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 | |
| ES2900253T3 (es) | Anticuerpos de dominio único dirigidos contra antígenos intracelulares | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| CO2017011093A2 (es) | Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienen | |
| RU2018102372A (ru) | Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
| CO2021013927A2 (es) | Protacs que degradan el receptor de estrógeno | |
| BR112020026432A2 (pt) | variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso | |
| MX2018009840A (es) | Sulfonilureas y compuestos relacionados y sus usos. | |
| EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| CA3031047A1 (en) | Isoquinoline derivatives as perk inhibitors | |
| PE20180573A1 (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| JP2018521116A (ja) | Axlインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 | |
| BR112016027778A2 (pt) | Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica | |
| EA201790949A1 (ru) | Замещенные 2,4-диаминохинолины в качестве новых противораковых средств | |
| RU2017112051A (ru) | Способ получения сложных эфиров астаксантина | |
| HRP20240605T1 (hr) | Kristalni oblici eravaciklina | |
| MY198902A (en) | 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases | |
| PE20181447A1 (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida | |
| EP4376859A4 (en) | SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES | |
| TWI850199B (zh) | 做為腺苷受體拮抗劑之噻唑并吡啶衍生物 | |
| RU2021124192A (ru) | Тиазолопиридиновые производные в качестве антагонистов аденозиновых рецепторов |